The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of...
MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Data demonstrates the potential of ‘1805 to reset the immune system through its unique mechanism of action across various autoimmune...
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to...
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment...
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery,...
Fireside chat scheduled for Wednesday, June 7, 2023, at 11:30 AM ETNEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- TG...
Common Shares to begin trading on adjusted basis June 6SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose...
SYDNEY, Australia and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX: CHM) (“Chimeric Therapeutics”, “Chimeric” or the...
MALVERN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which...
NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new...
LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its...
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on...
- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment - -...
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were...
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination biweekly regimen showed...
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion...